title: Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
abstract: OBJECTIVE
  To evaluate the efficiency and toxicities of nedaplatin and paclitaxel in patients with metastatic carcinoma of the esophagus.
  
  
  METHODS
  Thirty-nine untreated patients with confirmed metastatic tumors were enrolled. Patients were treated with nedaplatin 80 mg/m(2) and paclitaxel 175 mg/m(2) on day 1. Treatment was repeated every 21 days.
  
  
  RESULTS
  Thirty-six patients were eligible to be evaluated to have had a response. The overall response rate was 43.6% (17/39), with complete response and partial response rates of 2.6 and 41%, respectively. The median progression-free survival and overall survival time was 6.1 and 10.3 months, respectively. Grade 3/4 toxicities were only observed in six patients [neutropenia in three patients (7.7%) and nausea/vomiting in three patients (7.7%)].
  
  
  CONCLUSIONS
  Comparing to other regimens, combination of nedaplatin and paclitaxel achieved an encouraging clinical outcome, with relatively minimal toxicities for patients with metastatic esophageal carcinoma.
authors.affiliation: Department of Thoracic Oncology, Tumor Center, West China Hospital, Sichuan University, 610041, Chengdu, People's Republic of China.
authors.forename: Youling
authors.initials: Y
authors.lastname: Gong
authors.forename: Li
authors.initials: L
authors.lastname: Ren
authors.forename: Lin
authors.initials: L
authors.lastname: Zhou
authors.forename: Jiang
authors.initials: J
authors.lastname: Zhu
authors.forename: Meijuan
authors.initials: M
authors.lastname: Huang
authors.forename: Xiaojuan
authors.initials: X
authors.lastname: Zhou
authors.forename: Jin
authors.initials: J
authors.lastname: Wang
authors.forename: You
authors.initials: Y
authors.lastname: Lu
authors.forename: Mei
authors.initials: M
authors.lastname: Hou
authors.forename: Yuquan
authors.initials: Y
authors.lastname: Wei
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; C053989:nedaplatin; D017239:Paclitaxel